Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Summary

This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Timeline

Start

2013-04

Primary completion

2014-08

Completion

2014-08

Outcome

Met primary endpoint

registry analysis (non-inferiority or equivalence test); LCZ696 200 mg vs Olmesartan 20 mg; p <0.001; least Square Means net difference -2.33 (95% CI -4.00 to -0.66); ANCOVA NCT01785472 ↗

Drugs

Indications